Jonathan Smith writing for Labiotech reports that Dutch biotech venture Argenx has developed a llama-inspired antibody that has shown positive results with the potential to address autoimmune disease and acute myeloid leukemia (AML). This has stirred the attention of Janssen (JNJ) into a collaboration to advance research for use in cancer immunotherapy.
The company’s lead antibody efgartigimod has reduced the number of bleeding events I patients with autoimmune disorder primary immune thrombocytopenia. Efartigimod blocks proteins that recycle antibodies, reducing the level of antibodies attacking the platelets. In the trial extension, 67% of the 38 patients increased their platelet levels and ad reduced bleeds compared to the placebo.Source: labiotech